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Figure 1. A comparison of survival times in patients supplemented 
with or without ascorbate. adapted from cameron and pauling (18).
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Ascorbate (vitamin C) is a cofactor for a number of metabolic 
enzymes and is an indisputable essential vitamin C for 
humans. However, the potential of ascorbate as an anti-
cancer agent has been a topic of controversy. A number of 
previous reports have addressed both positive aspects and 
limitations of ascorbate in cancer therapy. In this review, we 
briefly summarize the potential antitumor effects of ascor-
bate and its prospects for clinical use.
[Immune Network 2009;9(5):147-152]
INTRODUCTION
The role of ascorbate (vitamin C) in cancer treatment is a sub-
ject with a controversial history (1,2). The core of this con-
troversy is the lack of reproducibility of the therapeutic effects 
of ascorbate on cancer patients (3), a problem compounded 
by uncertainties associated with deficiencies of independent 
pathologic  confirmation  and  failure  to  include  appropriate 
placebo groups in clinical studies (4-7). However, more re-
cent studies on the therapeutic effects of ascorbate have pro-
vided a clearer understanding of its effect in cancer treatment. 
The action of ascorbate in cancer cells has also been more 
clearly defined by in vitro studies. In this review, we summa-
rize these new findings and discuss the biological mechanism 
of  action  of  ascorbate  in  cancer  therapy.
HISTORY OF CANCER TREATMENT
Several  decades  ago,  McCormick,  Cameron  and  Rotman, 
without supporting data, postulated two hypotheses regarding 
the use of ascorbate for cancer therapy (8-10). One hypoth-
esis was that ascorbate exerts an antitumor effect by increas-
ing collagen synthesis (8,9). The other proposed that the anti-
cancer effects of ascorbate were due to inhibition of hyalur-
onidase,  which  decomposes  hyaluronic  acid  (10).  Pauling, 
Cameron and Leibovitz provided a scientific basis to support 
these  hypotheses,  which  they  subsequently  popularized 
(11,12).
    On the basis of an initial study of the antitumor effects of 
ascorbate in 50 patients with advanced cancer, Cameron and 
colleagues  concluded  that  high-dose  ascorbate  improved 
treatment outcome (12). Cameron and Pauling subsequently 
published the results of another clinical study in 1978 (3,13), 
showing that the long-term survival of cancer patients who 
r e c e i v e d  h i g h - d o s e  a s c o r b a t e  s u p p l e m e n t s  w a s  2 0  t i m e s  
greater than that of patient in the control group (Fig. 1) (14). 
In  addition,  a  prospective  study  published  in  1991  showed The Prospects of Vitamin C in Cancer Therapy
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Figure 2. Effect of ascorbate on 
IL-18 production. Adapted from Lee
WJ (39). B16F10 melanomas cells 
(2×10
5 cells/ml) were cultured in 
media with 0.2 mM ascorbate.
that survival of ascorbate-treated patients was 343 days com-
pared to 180 days for controls who did not receive ascorbate 
(15). However, Moertel and Mayo concluded that there was 
no significant difference in survival between ascorbate-treated 
a n d  - u n t r e a t e d  g r o u p s  ( 5 , 6 ) .  T h e  d i s c r e p a n c y  b e t w e e n  t h e  
findings of these studies may reflect differences in the route 
of ascorbate administration: Cameron administered ascorbate 
both orally and intravenously, whereas Moertel administered 
ascorbate exclusively through the oral route. These findings 
are summarized in Fig. 2 (16-18). In addition, the Mayo study 
was criticized because a majority of the enrolled patients had 
received prior chemotherapy, unlike the Cameron study, in 
which  a  minority  of  patients  (4/100)  had  been  previously 
treated with radiation and chemotherapy (14). Although the 
efficacy of ascorbate against cancer should be reassessed, tan-
talizing results from clinical studies argue that ascorbate may 
be a potential anticancer agent. The detailed analyses of as-
corbate  actions  in  cancer  cells  were  predicated  on  this 
possibility.
BIOLOGICAL ROLE
One biochemical function of ascorbate is to enhance hydrox-
ylation  in  a  large  number  of  biosynthetic  reactions  (19,20). 
In a majority of these biosynthetic processes, ascorbate pro-
vides necessary electrons to participating enzymes and is re-
quired to achieve full enzymatic activity (19). The character-
istic role of ascorbate is as a cofactor for prolyl and lysyl hy-
droxylase enzymes (20). Ascorbate is also necessary for cho-
lesterol  metabolism,  cytochrome  p450  activity  (21),  neuro-
transmitter synthesis (20) and the synthesis of carnitine from 
lysine (22,23). Importantly, ascorbate has dual properties in 
oxidative  processes,  acting  as  both  an  antioxidant  and  a 
prooxidant.
    Ascorbate is considered to be an important antioxidant in 
extracellular fluid (24); it also guards against aqueous radicals 
in  blood  (25)  and  protects  plasma  lipids  from  peroxidative 
damage  caused  by  peroxyl  radicals  (26).  Thus,  in  this  ca-
pacity,  ascorbate  protects  a  number  of  cells  and  tissues 
throughout the body from oxidative stress. Conversely, ascor-
bate also accelerates oxidative metabolism by preventing the 
use of pyruvate for glycolysis (27). This property helps to in-
hibit  the  proliferation  of  tumor  cells,  but  not  normal  cells 
(28-30). In a great number of malignant cancer cell lines, it 
is quite interesting that the cytotoxic effect of ascorbate is cor-
related  with  its  prooxidant  activity  (31-35).
VITAMIN C IN CANCER TREATMENT
Vitamin C as an immune-modulator
Ascorbate enhances resistance against pathogens by stimulat-
ing the immune system (36-38).  Recently, we reported that The Prospects of Vitamin C in Cancer Therapy
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Figure 3. A model inhibiting IL-18 networks by ascorbate. Ascorbate
inhibits IL-18-induced the immune escape of various cancer cells, 
including gastric, breast, leukemia, and melanomas.
Figure 4. A mechanism of preferential formation of ascorbate radicals
(Asc-) and H2O2 in extracellular fluid compared with blood. Adapted
from Levine (60).
ascorbate suppresses production of IL-18, a key regulator in 
malignant skin tumors, including melanomas and squamous 
cells carcinomas (Fig. 3) (39). IL-18 is known as an interfer-
on-γ-inducing factor, and is capable of stimulating interfer-
on-γ production by natural killer (NK) cells, activated macro-
phage, and T cells (40). Importantly, it has been recently re-
ported that IL-18 expression is positively correlated with vari-
ous  tumors  (41).
    In gastric cancer cells, IL-18 production is enhanced by vas-
cular endothelial growth factor (VEGF), resulting in increased 
IL-18-mediated  tumor  cell  migration  (42).  In  breast  cancer 
cells, IL-18 induces the expression of transferrin (43), which 
is a positive regulator of cell growth and proliferation (44). 
Thus, one mechanism by which ascorbate may be effective 
against  cancer  is  through  down-regulation  of  IL-18,  which 
plays an important role in controlling the escape of various 
cancer cells, including melanimas, gastric, and breast cancer 
c e l l s ,  f r o m  i m m u n e  s u r v e i l l a n c e  ( F i g .  4 ) .   
    Importantly, dosage is a key to the effectiveness of ascor-
bate as an immune-modulator. On the basis of the above re-
ports, we recently postulated that a dose of ascorbate, 100∼
250  μM  may  help  prevent  the  immune  escape  of  cancer 
cells. These dosages can be achieved by daily oral supple-
ments  of  ascorbate.
Alternative properties of vitamin C as an antioxidant 
and prooxidant
Ascorbate is the reduced form of vitamin C, which also exists 
physiologically  in  the  oxidized  form,  dehydroascorbic  acid 
(DHA). DHA is taken up into cells by glucose transporters 
(45,46). Inside the cell, it is reduced to ascorbic acid (45,46) 
and decreases intracellular ROS levels, thus acting initially as 
an  antioxidant  (47-49).  In  a  recent  study,  Conner  and  col-
leagues reported that all antineoplastic drugs tested produced 
mitochondrial  dysfunction,  including  loss  of  mitochondrial 
membrane  potential  and  an  increase  in  ROS  levels,  and 
showed  that  this  phenomenon  was  inhibited  by  vitamin  C. 
They postulated that vitamin C acts as an antioxidant to pro-
tect cells against mitochondrial dysfunction induced by anti-
neoplastic agents, and thus antagonizes the cytotoxic effects 
of antineoplastic drugs (50). In a similar vein, Blair cautioned 
that because vitamin C/d (200 mg) induced decomposition of 
lipid hydroperoxides to endogenous genotoxins, it might be 
counterproductive in cancer treatment (51,52). This study was 
also unable to find support for the notion that vitamin C in-
duced  lipid  peroxidation  (53).
    However, the emphasis of these studies in the potential an-
tioxidant properties of vitamin C overlooks the capacity of as-
corbate to act as a prooxidant. In our previous studies, we 
have shown that ascorbate induces apoptosis in B16F10 mur-
ine  melanomas  through  mitochondrial  dysfunction  (54).  A 
high dose of ascorbate induced a decrease in mitochondrial The Prospects of Vitamin C in Cancer Therapy
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Figure 5. Clinical studies of ascorbate and cancer survival (17).
membrane potential and a release of cytochrome c from mi-
tochondria to cytosol, which acted to promote apoptosis. A 
low dose of ascorbate induced cell-cycle arrest of cancer cells 
(55,56).  Thus,  the  effect  of  ascorbate  on  cancer  cells  was 
mediated by an increase in intracellular ROS levels. In addi-
tion, we showed that ascorbate, acting as a prooxidant, in-
hibited cancer cell growth through other mechanisms, includ-
ing induction of endoplasmic reticulum stress, suppression of 
insulin-like growth factor production, and inhibition of angio-
genic factor production (our unpublished data, 57,58). Levine 
and colleagues have also reported anticancer activities of as-
corbate  that  were  attributable  to  its  prooxidant  properties, 
showing  that  ascorbate  acts  as  a  prooxidant  and  decreases 
tumor growth in mice (59). They also showed that ascorbate 
produced hydrogen peroxide-dependent cytotoxicity in vari-
o u s  c a n c e r  c e l l s  w i t h o u t  a f f e c t i n g  n o r m a l  c e l l s .  M o r e  i m -
portantly, Levine suggested that ascorbate-induced formation 
of hydrogen peroxide preferentially occurs in extracellular flu-
id compared with blood (Fig. 5) (60). These studies provide 
a  mechanistic  basis  for  applying  ascorbate  as  a  prooxidant 
therapeutic  agent  for  cancer  treatment.
    Although ascorbate has shown inhibitory effects in a variety 
of cancer cells, including melanomas, brain tumor, prostate 
cancer, and stomach cancer cell, the relative chemosensitivity 
of  different  cancer  cells  to  ascorbate  varies.  This  potential 
drawback in an otherwise positive profile has not yet been 
fully  addressed,  despite  a  number  of  studies  that  have  at-
tempted to explain the mechanism-of-action of ascorbate in 
cancer cells. Prior to application of ascorbate in cancer ther-
apy, it will be necessary to fully elucidated the detailed mech-
anisms by which ascorbate inhibits cancer cell proliferation. 
CLINICAL TRIALS
Masaki Inoue suggested in his review that application of US 
National  Cancer  Institute  (NCI)  Best-Case  Series  guidelines 
(http://www.cancer.gov/cam/bestcase_intro.html) is one way 
to advance the clinical possibility of ascorbate for the cancer 
therapy  (16,61,62).  These  guidelines  comprise  several  stan-
dards.  First,  there  must  be  a  plausible  diagnosis  of  cancer 
based on a clinic examination, preferably including a tissue 
biopsy.  Second,  the  patient  should  not  be  treated  con-
currently with ascorbate and other therapeutic modalities, in-
cluding radiation and chemotherapy. Third, the treatment his-
tory  of  patient  should  be  known. One  such  study  of three 
carcinoma cases documented by Padayatty and conducted in 
accordance  with  NCI  Best-Case  Series  guidelines  (16,63) 
showed that cancer progression was significantly suppressed 
by high-dose intravenous vitamin C therapy. More such clin-
ical studies, in conjunction with additional basic research, are 
needed to buttress the scientific support for the clinical plausi-
bility  of  using  vitamin  C  in  the  treatment  of  cancer. 
CONCLUSION
S e v e r a l  l i n e s  o f  e v i d e n c e  s u p p o r t  t h e  n o t i o n  t h a t  a s c o r b a t e 
improves the well-being and survival of cancer patients, espe-
cially when administered intravenously. The beneficial effects 
of ascorbate in cancer treatment reflect the ability of ascorbate 
to inhibit cancer cell proliferation. We also suggest that oral 
administration of ascorbate can inhibit the immune escape of 
cancer cells through suppression of IL-18 expression. Impor-
tantly, ascorbate is not cytotoxic towards normal cells; thus, 
ascorbate may be a model antineoplastic agent, prolongling 
survival  and  improving  the  quality  of  life  through  selective 
inhibition  of  tumor  growth.
    Based  on  the  collective  evidence,  we  propose  that  acor-
bate,  especially  intravenous  ascorbate,  would  be  a  helpful 
medicine in cancer therapy, and we encourage more in vitro 
preclinical  studies  to  determine  its  detailed  mechanisms- 
of-action  in  cancer  cells.
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